title: BRAF targeted therapy changes the treatment paradigm in melanoma.
abstract: After decades of stagnation, recent therapeutic advances in melanoma seem on the horizon. The discovery of the genetic underpinnings of this historically refractory disease has exposed potential targets for therapy, BRAF mutations being principal among them. In the 8 years following the discovery of BRAF mutations in 50-60% of advanced melanomas, only recently have potent and selective inhibitors of this intracellular signaling molecule shown efficacy from early clinical testing. Vemurafenib (PLX4032) and GSK2118436, two orally available and well tolerated agents are on the verge of transforming the landscape of melanoma therapy based on the promising results of their respective phase I, II, and III trials.
authors: Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles, and Jonsson Comprehensive Cancer Center at UCLA, 11-934 Factor Building, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA.
authors: Antoni
authors: A
authors: Ribas
authors: Keith T
authors: KT
authors: Flaherty
references: Nature. 2006 Jan 19;439(7074):358-62
references: 16273091
references: Cancer Cell. 2002 Aug;2(2):117-25
references: 12204532
references: Nature. 2002 Jun 27;417(6892):949-54
references: 12068308
references: Chem Biol. 1999 Aug;6(8):559-68
references: 10421767
references: Clin Cancer Res. 2010 Dec 15;16(24):6040-8
references: 21169256
references: Cancer Cell. 2010 Dec 14;18(6):683-95
references: 21156289
references: Cancer Res. 2003 Jul 15;63(14):3883-5
references: 12873977
references: Cancer Res. 2008 Jun 15;68(12):4853-61
references: 18559533
references: N Engl J Med. 2004 Sep 2;351(10):998-1012
references: 15342808
references: J Biol Chem. 2009 Jan 30;284(5):3183-3194
references: 19049963
references: N Engl J Med. 2010 Aug 26;363(9):809-19
references: 20818844
references: Nature. 2010 May 27;465(7297):473-7
references: 20505728
references: PLoS One. 2008 Jul 16;3(7):e2734
references: 18628967
references: N Engl J Med. 2010 Aug 19;363(8):711-23
references: 20525992
references: Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2301s-2307s
references: 16609049
references: Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14903-8
references: 20668238
references: Nature. 1984 Oct 18-24;311(5987):671-3
references: 6090953
references: Br J Cancer. 2006 Sep 4;95(5):581-6
references: 16880785
references: Nature. 2010 Dec 16;468(7326):973-7
references: 21107323
references: Nat Rev Cancer. 2008 Apr;8(4):299-308
references: 18354418
references: Crit Rev Immunol. 1997;17(2):155-78
references: 9094451
references: J Immunol. 2006 Apr 15;176(8):4757-65
references: 16585569
references: Mol Cancer Res. 2006 Oct;4(10):779-92
references: 17050671
references: J Transl Med. 2010 Apr 20;8:39
references: 20406486
references: Cancer Res. 2010 Jul 1;70(13):5213-9
references: 20551059
references: Cancer Res. 2006 Jan 15;66(2):999-1006
references: 16424035
references: J Invest Dermatol. 2006 Jan;126(1):154-60
references: 16417231
references: Nature. 2010 Mar 18;464(7287):427-30
references: 20179705
references: Nature. 2010 Dec 16;468(7326):968-72
references: 21107320
references: Cancer Cell. 2009 Apr 7;15(4):294-303
references: 19345328
references: Cell. 2010 Jan 22;140(2):209-21
references: 20141835
references: Dis Model Mech. 2009 Jul-Aug;2(7-8):399-411
references: 19470611
references: Cell. 2004 Mar 19;116(6):855-67
references: 15035987
references: Nature. 2010 Sep 30;467(7315):596-9
references: 20823850
references: Nat Rev Cancer. 2006 Aug;6(8):593-602
references: 16862190
references: Am J Dermatopathol. 2003 Oct;25(5):365-70
references: 14501284
references: Nature. 2010 Mar 18;464(7287):431-5
references: 20130576
references: Cancer Res. 2007 Jan 1;67(1):122-9
references: 17210691
references: Br J Cancer. 2010 Jun 8;102(12):1724-30
references: 20531415
references: Nature. 1984 Feb 16-22;307(5952):658-60
references: 6694757
references: Cancer Res. 2006 Dec 1;66(23):11100-5
references: 17145850
references: N Engl J Med. 2005 Nov 17;353(20):2135-47
references: 16291983
references: Clin Cancer Res. 2008 Jul 15;14(14):4385-91
references: 18628452
references: N Engl J Med. 2004 May 20;350(21):2129-39
references: 15118073
references: Nature. 1986 Jul 3-9;322(6074):78-80
references: 3014349
references: J Clin Oncol. 2004 Nov 15;22(22):4456-62
references: 15483017
references: N Engl J Med. 2001 Apr 5;344(14):1031-7
references: 11287972
references: Nature. 2007 Feb 22;445(7130):851-7
references: 17314971
references: N Engl J Med. 2002 Aug 15;347(7):472-80
references: 12181401
references: N Engl J Med. 2010 Oct 28;363(18):1693-703
references: 20979469
references: Mol Cancer Ther. 2006 May;5(5):1136-44
references: 16731745
references: Oncogene. 2009 Jan 8;28(1):85-94
references: 18794803
references: N Engl J Med. 2008 Jun 19;358(25):2698-703
references: 18565862
references: Nat Genet. 2009 May;41(5):544-52
references: 19282848